News releases
10 of 52 items
FAQs following the General Meeting on 18 May 2010 19 May 2010
Result of General Meeting 18 May 2010
Neuropharm Group plc (AIM: NPH) confirms that at the General Meeting held earlier today, the Resolution set out in the circular sent to shareholders on 20 April 2010 to effect a winding up of the Company by way of a members’ voluntary liquidation (“MVL”) and the cancellation of admission to trading of the Company’s securities on AIM was duly passed. Cancellation of admission is therefore expected to occur at 7.00 a.m. tomorrow, 19 May 2010. The result of the GM was 21,975,056 votes in favour of the Resolution, no votes against and no abstentions.
Issue of Equity 30 Apr 2010
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, announces the issue of 1,200,000 new ordinary shares of 10p each in the Company (“Ordinary Shares”) following the exercise of options granted to Professor Eric Hollander and Professor Mark Smith in March 2006. As a result, the Company’s issued share capital now consists of 32,736,697 ordinary shares of 10p each, with one voting right per share. The Company holds no ordinary shares in Treasury, therefore, the total number of voting rights in the Company is 32,736,697.
Proposed Members’ Voluntary Liquidation and proposed cancellation of admission of Ordinary Shares to trading on AIM 20 Apr 2010
Neuropharm Group plc (AIM: NPH) today announces that its directors have decided to recommend to shareholders that the Company be wound up by way of a members’ voluntary liquidation (“MVL”) such that, following payment of the Company’s liabilities, its remaining cash be returned to shareholders. The MVL is conditional upon approval by Neuropharm shareholders (“Shareholders”) at a general meeting (the “General Meeting”), to be held on Tuesday 18 May 2010. The Company also announces that it has applied for the cancellation of the trading of its securities on AIM, subject to approval by Shareholders of the MVL. A single resolution (the “Resolution”) will be proposed to Shareholders at the General Meeting to approve the MVL and the cancellation. It is expected that suspension of the Company’s ordinary shares (the “Ordinary Shares”) will occur at 7.00 a.m. on Tuesday 18 May 2010 and, subject to the passing of the Resolution, that cancellation will occur at 7.00 a.m. on the following day, Wednesday 19 May 2010.
Board Change 9 Apr 2010
Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, announces that Dr Mike Snape is stepping down from his position as Chief Scientific Officer and from the board of the Neuropharm Group with effect from 9th April. The Board would like to thank Dr Snape for his considerable contribution as a founder of the Company and Chief Scientific Officer since its inception in 2005.
Offer Update 31 Mar 2010
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, provides the following update to shareholders.
Half-year results for the six months ended 31 December 2009 23 Mar 2010
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today announces its half-year results for the six months ended 31 December 2009.
Offer Update 10 Mar 2010
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company.
Result of AGM 9 Dec 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, held its Annual General Meeting earlier today at which all resolutions were duly passed.
Continuing Discussions 8 Dec 2009
Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company, as announced on 3 November 2009.
10 of 52 items